Hancock Whitney Corp Sells 103,479 Shares of DexCom, Inc. (NASDAQ:DXCM)

Hancock Whitney Corp lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 94.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,312 shares of the medical device company’s stock after selling 103,479 shares during the period. Hancock Whitney Corp’s holdings in DexCom were worth $423,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Jennison Associates LLC raised its holdings in DexCom by 1,683.2% in the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after purchasing an additional 6,544,102 shares in the last quarter. Westfield Capital Management Co. LP grew its position in shares of DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after buying an additional 876,739 shares during the period. Canada Pension Plan Investment Board increased its stake in shares of DexCom by 189.1% in the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock worth $75,471,000 after acquiring an additional 435,401 shares in the last quarter. Intech Investment Management LLC lifted its position in DexCom by 2,083.0% during the 3rd quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock valued at $25,967,000 after acquiring an additional 369,587 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its holdings in DexCom by 16.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after purchasing an additional 353,019 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

NASDAQ:DXCM opened at $78.10 on Thursday. The business’s 50-day simple moving average is $71.11 and its two-hundred day simple moving average is $88.51. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The stock has a market cap of $30.51 billion, a PE ratio of 46.77, a P/E/G ratio of 2.38 and a beta of 1.17. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,431 shares of company stock valued at $399,319. 0.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on DXCM shares. Piper Sandler reissued an “overweight” rating and issued a $90.00 target price on shares of DexCom in a research note on Monday, August 26th. Oppenheimer reduced their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Stifel Nicolaus upped their price objective on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, August 23rd. Robert W. Baird lifted their price target on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. Finally, Raymond James reduced their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.